By Zachary Zagger ( March 18, 2015, 1:49 PM EDT) -- Epizyme Inc., a biopharmaceutical company developing cancer therapies, priced a $124.5 million public offering of shares on Tuesday, less than a week after the company announced it is reacquiring global rights to one of its cancer treatments....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.